Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Heterogeneous clinical responses to histone deacetylase inhibitors (HDACi) in diffuse large B-cell lymphoma (DLBCL) have prompted a need for evaluating the impact of mutations in the histone acetyl transferases (HAT) CREBBP and EP300 on HDACi treatment outcome. We identified four DLBCL cell lines; Toledo, with mutations in CREBBP and EP300 , SUDHL-7 with mutation of CREBBP and wild-type (wt) EP300 , RL with mutation of EP300 and wt CREBBP , and U2932 with wt CREBBP and wt EP300 . Vorinostat treatment induced apoptosis significantly more rapid and profound in the CREBBP/EP300 double mutant cell line. Our results suggest that pre-treatment stratification according to HAT defects may be relevant in DLBCL
Originalsprog | Engelsk |
---|---|
Tidsskrift | Leukemia Research Reports |
Vol/bind | 2 |
Udgave nummer | 1 |
Sider (fra-til) | 1-3 |
Antal sider | 3 |
ISSN | 2213-0489 |
DOI | |
Status | Udgivet - 2012 |
ID: 332928345